Amundi MSCI Europe II UCITS ETF (EPA: MEU)
France
· Delayed Price · Currency is EUR 191.13
-0.07 (-0.04%)
Aug 30, 2024, 5:35 PM CET
17.14% (1Y)
| Assets | 760.93M |
| Expense Ratio | 0.25% |
| PE Ratio | 14.52 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +17.17% |
| Volume | 1,382 |
| Open | 189.79 |
| Previous Close | 191.20 |
| Day's Range | 189.79 - 191.88 |
| 52-Week Low | 152.61 |
| 52-Week High | 191.88 |
| Beta | 1.00 |
| Holdings | 420 |
| Inception Date | Jan 10, 2006 |
About MEU
Amundi MSCI Europe II UCITS ETF is an exchange traded fund launched and managed by Amundi Asset Management SAS. It invests in the public equity markets of developed countries in Europe. The fund uses derivatives such as swap agreements to invest in the stocks of companies operating across diversified sectors. It invests in the stocks of large-cap and mid-cap companies. The fund seeks to replicate the performance of the MSCI Europe Net Return EUR Index, by employing synthetic replication methodology. Amundi MSCI Europe II UCITS ETF was formed on December 13, 2005 and is domiciled in France.
Asset Class Equity
Category Total Market
Stock Exchange Euronext Paris
Ticker Symbol MEU
Provider Lyxor
Index Tracked MSCI Europe
Performance
MEU had a total return of 17.17% in the past year. Since the fund's inception, the average annual return has been 2.44%, including dividends.
Top 10 Holdings
23.17% of assets| Name | Symbol | Weight |
|---|---|---|
| Novo Nordisk A/S | NOVO.B | 3.84% |
| ASML Holding N.V. | ASML | 3.11% |
| Nestle SA | NESN.SW | 2.51% |
| AstraZeneca PLC | AZN | 2.37% |
| Novartis AG Registered Shares | NOVN.SW | 2.08% |
| Roche Holding AG | ROG.SW | 2.06% |
| Shell plc | SHEL | 2.00% |
| SAP SE | SAP | 1.99% |
| LVMH Moët Hennessy - Louis Vuitton, Société Européenne | MC | 1.78% |
| HSBC Holdings plc | HSBA | 1.43% |